A hydrophilic polymer comprising pendent groups of the formula I: Wherein: W is independently selected from —OH, —COOH, —SO.sub.3H, —OPO.sub.3H, —O—(C.sub.1-4alkyl), —O—(C.sub.1-4alkyl)OH, —O—(C.sub.1-4alkyl)R.sup.2, —O—(C.sub.2H.sub.5O).sub.qR.sup.1—(C═O)—O—C.sub.1-4alkyl and —O—(C═O)C.sub.1-4alkyl; or a group —BZ; wherein —OH, COOH, O—PO.sub.3H and SO.sub.3H maybe in the form of a pharmaceutically acceptable salt; wherein: B is a bond, or a straight branched alkanediyl, oxyalkylene, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and Z is an ammonium, phosphonium, or sulphonium phosphate or phosphonate ester zwitterionic group; X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; G is a coupling group through which the group of the formula I is coupled to the polymer and is selected from ether, ester, amide, carbonate, carbamate, 1,3 dioxolone, and 1,3 dioxane; R.sup.1 is H or C.sub.1-4 alkyl; R.sup.2 is —COOH, —SO.sub.3H, or —OPO.sub.3H.sub.2 q is an integer from 1 to 4; n is an integer from 1 to 4; p is an integer from 1 to 3; and n+p is from 2 to 5; and wherein —COOH, —OPO.sub.3H.sub.2 and —SO.sub.3H as well as phenolic —OH maybe in the form of a pharmaceutically acceptable salt.

The present invention provides methods of synthesizing D-α-methyldopa and L-α-methyldopa.

The present invention provides methods of synthesizing D-α-methyldopa and L-α-methyldopa.

The present invention provides methods of synthesizing D-α-methyldopa and L-α-methyldopa.

Various salts of tranexamic acid esters compounds are described, along with compositions including such compounds. Methods of use for treatment of external surfaces (e.g. skin) and processes of producing the compounds and compositions are also described.

Various salts of tranexamic acid esters compounds are described, along with compositions including such compounds. Methods of use for treatment of external surfaces (e.g. skin) and processes of producing the compounds and compositions are also described.

A compound having Formula (I) or Formula (II):

##STR00001##

or a mixture thereof,

in which R is —H; —CH.sub.3; —CH—(CH.sub.3).sub.2; —CH.sub.2—CH—(CH.sub.3).sub.2; —CH—(CH.sub.3)—CH.sub.2—CH.sub.3; —CH.sub.2—(C.sub.6H.sub.5); —CH.sub.2—(3-indole); —CH.sub.2—CH.sub.2—S—CH.sub.3; —CH.sub.2—OH; —CH—(CH.sub.3)—OH; —CH.sub.2—SH; —CH.sub.2-(p-C.sub.6H.sub.40H); —CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—NH.sub.2; —CH.sub.2—CO—NH.sub.2; —CH.sub.2—CH.sub.2—CO—NH.sub.2; —CH.sub.2—CH.sub.2—COOH; —CH.sub.2—COOH; or —CH.sub.2—CH.sub.2—NH—C═NH.sub.2(NH.sub.2);

and X is a suitable non-interfering anion, a process for making the compound having Formula (I) or Formula (II), and a process for reacting the compound having Formula (I) or Formula (II) or a mixture thereof with a (poly)saccharide to form a cationized (poly)saccharide.

A compound having Formula (I) or Formula (II):

##STR00001##

or a mixture thereof,

in which R is —H; —CH.sub.3; —CH—(CH.sub.3).sub.2; —CH.sub.2—CH—(CH.sub.3).sub.2; —CH—(CH.sub.3)—CH.sub.2—CH.sub.3; —CH.sub.2—(C.sub.6H.sub.5); —CH.sub.2—(3-indole); —CH.sub.2—CH.sub.2—S—CH.sub.3; —CH.sub.2—OH; —CH—(CH.sub.3)—OH; —CH.sub.2—SH; —CH.sub.2-(p-C.sub.6H.sub.40H); —CH.sub.2—CH.sub.2—CH.sub.2—CH.sub.2—NH.sub.2; —CH.sub.2—CO—NH.sub.2; —CH.sub.2—CH.sub.2—CO—NH.sub.2; —CH.sub.2—CH.sub.2—COOH; —CH.sub.2—COOH; or —CH.sub.2—CH.sub.2—NH—C═NH.sub.2(NH.sub.2);

and X is a suitable non-interfering anion, a process for making the compound having Formula (I) or Formula (II), and a process for reacting the compound having Formula (I) or Formula (II) or a mixture thereof with a (poly)saccharide to form a cationized (poly)saccharide.

A crystal of a 1,3,5-triazine derivative or a solvate thereof, and a method for producing the same are provided. The present invention relates to a crystal of a compound represented by Formula (I) or a solvate thereof:

##STR00001## and relates to a pharmaceutical composition containing the same. The present invention also relates to a crystal of a compound represented by Formula (I), or a solvate thereof.

A crystal of a 1,3,5-triazine derivative or a solvate thereof, and a method for producing the same are provided. The present invention relates to a crystal of a compound represented by Formula (I) or a solvate thereof:

##STR00001## and relates to a pharmaceutical composition containing the same. The present invention also relates to a crystal of a compound represented by Formula (I), or a solvate thereof.